Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Zuberitamab Injection.

Zebetuzumab is a targeted drug suitable for adult patients with CD20-positive diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). You can go to the hospital for treatment, seek the help of professional doctors, and use it under the guidance of doctors.

Zebetuzumab is mostly an injection, which is mainly a human-mouse chimeric monoclonal antibody targeting the CD20 antigen on the surface of B cells. It can specifically bind to the CD20 antigen on the surface of B cells, thereby initiating the immune response of B cell lysis, acting on tumors, and then exerting anti-tumor effects. In clinical practice, it is mainly combined with cyclophosphamide, doxorubicin, vincristine, and prednisone for treatment.

When using it, some people may have abnormal blood routine, such as decreased white blood cell count, decreased neutrophil count, decreased lymphocyte count, and decreased platelet count. In addition, anemia, fever, nausea, vomiting and other adverse reactions may also occur. If you feel uncomfortable, you should communicate with your doctor as soon as possible to change the medicine or adjust the dose to avoid harming your health.